Clinical Trial Update: LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update indicating completion of a study evaluating Lantus Continuous Glucose Monitoring Subcutaneous for Diabetes Mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus | Phase 4 | Status: COMPLETED